This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (amended): A method to treat spinal cord damage; spinal cord trauma; neuronal tissue damage produced by an ischemic attack, infarction, hemorrhage or aneurysm; Huntington's disease; multiple sclerosis; myelopathy; myelitis; or syringomyelia, comprising administering to a patient in need thereof an effective amount of an FGF-20 polypeptide or a biologically active fragment thereof.

Claim 2 (original): The method of claim 1, wherein said FGF-20 polypeptide is human.

Claim 3 (original): The method of claim 2, wherein said polypeptide has FGF-20 specific immunogenic activity.

Claim 4 (original): The method of claim 1, wherein said polypeptide comprises amino acid 1 to amino acid 211 as set forth in Fig. 1.

Claim 5 (amended): The method of claim 1,wherein said polypeptide has 95% sequence identity to amino acid 1 to amino acid 211 of human FGF-20 as set forth in Fig. 1, and wherein said ~~FGF-20~~ polypeptide has FGF activity.

Claim 6 (amended): The method of claim 2,wherein said polypeptide has 95% sequence identity to amino acid 1 to amino acid 211 of human FGF-20 as set forth in Fig. 1, and wherein said ~~FGF-20~~ polypeptide has FGF activity.

Claim 7 (amended): A method to treat spinal cord damage; spinal cord trauma; neuronal tissue damage produced by an ischemic attack, infarction, hemorrhage or aneurysm; Huntington's disease; multiple sclerosis; myelopathy; myelitis; or syringomyelia, comprising

administering to a patient in need thereof an effective amount of a nucleic acid having a nucleotide sequence coding for an FGF-20 polypeptide or a biologically active fragment thereof.

Claim 8 (amended): The method of claim 7, wherein said ~~nucleic acid~~ FGF-20 polypeptide is human.

Claim 9 (original): The method of claim 8, wherein the nucleotide sequence codes without interruption for FGF-20.

Claim 10 (original): The method of claim 7, wherein the nucleotide sequence has 95% sequence identity to the nucleotide sequence set forth in Fig. 1.

Claim 11 (original): The method of claim 8, wherein the nucleotide sequence has 95% sequence identity to the nucleotide sequence set forth in Fig. 1.

Claim 12 (amended): A method to treat an adrenal leukodystrophy, progressive multifocal leukoencephalopathy, encephalomyelitis, Guillian-Barre syndrome, paraproteinemia, or chronic inflammatory demyelinating polyneuropathy, comprising administering to a patient in need thereof an effective amount of an FGF-20 polypeptide or a biologically active fragment thereof.

B' Cont

Claim 13 (original): The method of claim 12, wherein said FGF-20 polypeptide is human.

Claim 14 (original): The method of claim 13, wherein said polypeptide has FGF-20 specific immunogenic activity.

Claim 15 (original): The method of claim 12, wherein said polypeptide comprises amino acid 1 to amino acid 211 as set forth in Fig. 1.

Claim 16 (amended): The method of claim 12, wherein said polypeptide has 95% sequence identity to amino acid 1 to amino acid 211 of human FGF-20 as set forth in Fig. 1, and wherein said ~~FGF-20~~ polypeptide has FGF activity.

Claim 17 (amended): The method of claim 13, wherein said polypeptide has 95% sequence identity to amino acid 1 to amino acid 211 of human FGF-20 as set forth in Fig. 1, and wherein said ~~FGF-20~~ polypeptide has FGF activity.

Claim 18 (original): A method to treat an adrenal leukodystrophy, progressive multifocal leukoencephalopathy, encephalomyelitis, Guillian-Barre syndrome, paraproteinemia, or chronic inflammatory demyelinating polyneuropathy, comprising administering to a patient in need thereof an effective amount of a nucleic acid having a nucleotide sequence coding for an FGF-20 polypeptide or a biologically active fragment thereof.

Claim 19 (original): The method of claim 18, wherein said ~~nucleic acid~~ FGF-20 polypeptide is human.

B' Cont

Claim 20 (original): The method of claim 19, wherein the nucleotide sequence codes without interruption for FGF-20.

Claim 21 (original): The method of claim 18, wherein the nucleotide sequence has 95% sequence identity to the nucleotide sequence set forth in Fig. 1.

Claim 22 (original) The method of claim 19, wherein the nucleotide sequence has 95% sequence identity to the nucleotide sequence set forth in Fig. 1.

Claim 23 (original): A method to promote graft survival, comprising administering to a patient in need thereof an effective amount of an FGF-20 polypeptide or a biologically active

fragment thereof.

Claim 24 (original) The method of claim 23, wherein said FGF-20 polypeptide is human.

Claim 25 (original): The method of claim 24, wherein said polypeptide has FGF-20 specific immunogenic activity.

Claim 26 (original): The method of claim 23, wherein said polypeptide comprises amino acid 1 to amino acid 211 as set forth in Fig. 1.

Claim 27 (amended): The method of claim 23, wherein said polypeptide has 95% sequence identity to amino acid 1 to amino acid 211 of human FGF-20 as set forth in Fig. 1, and wherein said ~~FGF-20~~ polypeptide has FGF activity.

Claim 28 (original): The method of claim 24, wherein said polypeptide has 95% sequence identity to amino acid 1 to amino acid 211 of human FGF-20 as set forth in Fig. 1, and wherein said ~~FGF-20~~ polypeptide has FGF activity.

B1 CONT

Claim 29 (original): A method to promote graft survival, comprising administering to a patient in need thereof an effective amount of a nucleic acid having a nucleotide sequence coding for an FGF-20 polypeptide or a biologically active fragment thereof.

Claim 30 (amended): The method of claim 29, wherein said ~~nucleic acid~~ FGF-20 polypeptide is human.

Claim 31 (original) The method of claim 30, wherein the nucleotide sequence codes without interruption for FGF-20.

Claim 32 (original) The method of claim 29, wherein the nucleotide sequence has 95%

sequence identity to the nucleotide sequence set forth in Fig. 1.

Claim 33 (original) The method of claim 30, wherein the nucleotide sequence has 95% sequence identity to the nucleotide sequence set forth in Fig. 1.

B'

Claim 34 (Newly added): The method of claim 1 to treat multiple sclerosis.

Claim 35 (Newly added): The method of claim 7 to treat multiple sclerosis.